What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?

Yu Shyr; Derek Shyr

doi:10.1001/jamaoncol.2020.1847

What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?

Yu Shyr, Derek Shyr

Department of Statistics

Research output: Contribution to journal › Editorial › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	1334-1335
Number of pages	2
Journal	JAMA Oncology
Volume	6
Issue number	9
DOIs	https://doi.org/10.1001/jamaoncol.2020.1847
Publication status	Published - 2020 Sept

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2020.1847

Cite this

@article{115b121f649341c5a0e6e47ba6c503e0,

title = "What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?",

author = "Yu Shyr and Derek Shyr",

year = "2020",

month = sep,

doi = "10.1001/jamaoncol.2020.1847",

language = "English",

volume = "6",

pages = "1334--1335",

journal = "JAMA Oncology",

issn = "2374-2437",